The U.S. Department of Veterans Affairs (VA) has announced plans to initiate new research studies on the use of psychedelic compounds for treating post-traumatic stress disorder (PTSD) and depression in veterans. This marks the first significant scientific inquiry by the VA into psychedelics since the 1960s. The focus will be on substances like methylenedioxymethamphetamine (MDMA) and psilocybin, which have shown positive impacts in mental health treatment. However, prior research has largely excluded veterans, necessitating a more focused investigation into how these treatments could affect this specific group.
The VA’s initiative aims to understand the effectiveness and safety of using MDMA and psilocybin-augmented psychotherapy in veterans. Previous studies on psychedelics conducted in federal facilities did not use VA funding. The new research efforts, backed by the VA, come after discussions among federal clinicians, scientists, and policymakers about integrating medical psychedelic use into VA care. Congressional support has also emerged for further exploration of these compounds’ benefits for troops and veterans.
VA Secretary Denis McDonough expressed that this move represents a vital step towards exploring new, promising treatments that could enhance the health and quality of life for veterans. However, the VA cautions against the use of these substances as part of self-treatment programs by veterans.
Best Coverage:
